Cargando…

Performance Evaluation of the PowerChek SARS-CoV-2, Influenza A & B Multiplex Real-Time PCR Kit in Comparison with the BioFire Respiratory Panel

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and influenza viruses may pose enormous challenges to our healthcare system. We evaluated the performance of the PowerChek SARS-CoV-2, Influenza A & B Multiplex Real-time PCR Kit (PowerChek; Kogene Biotech, Seoul, Korea) in comparison...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Tae Yeul, Kim, Ji-Youn, Shim, Hyang Jin, Yun, Sun Ae, Jang, Ja-Hyun, Huh, Hee Jae, Kim, Jong-Won, Lee, Nam Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society for Laboratory Medicine 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859561/
https://www.ncbi.nlm.nih.gov/pubmed/35177568
http://dx.doi.org/10.3343/alm.2022.42.4.473
_version_ 1784654488698617856
author Kim, Tae Yeul
Kim, Ji-Youn
Shim, Hyang Jin
Yun, Sun Ae
Jang, Ja-Hyun
Huh, Hee Jae
Kim, Jong-Won
Lee, Nam Yong
author_facet Kim, Tae Yeul
Kim, Ji-Youn
Shim, Hyang Jin
Yun, Sun Ae
Jang, Ja-Hyun
Huh, Hee Jae
Kim, Jong-Won
Lee, Nam Yong
author_sort Kim, Tae Yeul
collection PubMed
description Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and influenza viruses may pose enormous challenges to our healthcare system. We evaluated the performance of the PowerChek SARS-CoV-2, Influenza A & B Multiplex Real-time PCR Kit (PowerChek; Kogene Biotech, Seoul, Korea) in comparison with the BioFire Respiratory Panels 2 and 2.1 (RP2 and RP2.1; bioMérieux, Marcy l’Étoile, France), using 147 nasopharyngeal swabs. The limit of detection (LOD) of the PowerChek assay was determined using SARS-CoV-2, influenza A, and B RNA standards. The LOD values of the PowerChek assay for SARS-CoV-2 and influenza A and B were 1.12, 1.24, and 0.61 copies/μL, respectively. The positive and negative percent agreements of the PowerChek assay compared with RP2 and RP2.1 were 97.5% (39/40) and 100% (107/107) for SARS-CoV-2; 100% (39/39) and 100% (108/108) for influenza A; and 100% (35/35) and 100% (112/112) for influenza B, respectively. The performance of the PowerChek assay was comparable to that of RP2 and RP2.1 for detecting SARS-CoV-2 and influenza A and B, suggesting its use in diagnosing SARS-CoV-2 and influenza infections.
format Online
Article
Text
id pubmed-8859561
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Korean Society for Laboratory Medicine
record_format MEDLINE/PubMed
spelling pubmed-88595612022-07-01 Performance Evaluation of the PowerChek SARS-CoV-2, Influenza A & B Multiplex Real-Time PCR Kit in Comparison with the BioFire Respiratory Panel Kim, Tae Yeul Kim, Ji-Youn Shim, Hyang Jin Yun, Sun Ae Jang, Ja-Hyun Huh, Hee Jae Kim, Jong-Won Lee, Nam Yong Ann Lab Med Brief Communications Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and influenza viruses may pose enormous challenges to our healthcare system. We evaluated the performance of the PowerChek SARS-CoV-2, Influenza A & B Multiplex Real-time PCR Kit (PowerChek; Kogene Biotech, Seoul, Korea) in comparison with the BioFire Respiratory Panels 2 and 2.1 (RP2 and RP2.1; bioMérieux, Marcy l’Étoile, France), using 147 nasopharyngeal swabs. The limit of detection (LOD) of the PowerChek assay was determined using SARS-CoV-2, influenza A, and B RNA standards. The LOD values of the PowerChek assay for SARS-CoV-2 and influenza A and B were 1.12, 1.24, and 0.61 copies/μL, respectively. The positive and negative percent agreements of the PowerChek assay compared with RP2 and RP2.1 were 97.5% (39/40) and 100% (107/107) for SARS-CoV-2; 100% (39/39) and 100% (108/108) for influenza A; and 100% (35/35) and 100% (112/112) for influenza B, respectively. The performance of the PowerChek assay was comparable to that of RP2 and RP2.1 for detecting SARS-CoV-2 and influenza A and B, suggesting its use in diagnosing SARS-CoV-2 and influenza infections. Korean Society for Laboratory Medicine 2022-07-01 2022-07-01 /pmc/articles/PMC8859561/ /pubmed/35177568 http://dx.doi.org/10.3343/alm.2022.42.4.473 Text en © Korean Society for Laboratory Medicine https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Communications
Kim, Tae Yeul
Kim, Ji-Youn
Shim, Hyang Jin
Yun, Sun Ae
Jang, Ja-Hyun
Huh, Hee Jae
Kim, Jong-Won
Lee, Nam Yong
Performance Evaluation of the PowerChek SARS-CoV-2, Influenza A & B Multiplex Real-Time PCR Kit in Comparison with the BioFire Respiratory Panel
title Performance Evaluation of the PowerChek SARS-CoV-2, Influenza A & B Multiplex Real-Time PCR Kit in Comparison with the BioFire Respiratory Panel
title_full Performance Evaluation of the PowerChek SARS-CoV-2, Influenza A & B Multiplex Real-Time PCR Kit in Comparison with the BioFire Respiratory Panel
title_fullStr Performance Evaluation of the PowerChek SARS-CoV-2, Influenza A & B Multiplex Real-Time PCR Kit in Comparison with the BioFire Respiratory Panel
title_full_unstemmed Performance Evaluation of the PowerChek SARS-CoV-2, Influenza A & B Multiplex Real-Time PCR Kit in Comparison with the BioFire Respiratory Panel
title_short Performance Evaluation of the PowerChek SARS-CoV-2, Influenza A & B Multiplex Real-Time PCR Kit in Comparison with the BioFire Respiratory Panel
title_sort performance evaluation of the powerchek sars-cov-2, influenza a & b multiplex real-time pcr kit in comparison with the biofire respiratory panel
topic Brief Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8859561/
https://www.ncbi.nlm.nih.gov/pubmed/35177568
http://dx.doi.org/10.3343/alm.2022.42.4.473
work_keys_str_mv AT kimtaeyeul performanceevaluationofthepowercheksarscov2influenzaabmultiplexrealtimepcrkitincomparisonwiththebiofirerespiratorypanel
AT kimjiyoun performanceevaluationofthepowercheksarscov2influenzaabmultiplexrealtimepcrkitincomparisonwiththebiofirerespiratorypanel
AT shimhyangjin performanceevaluationofthepowercheksarscov2influenzaabmultiplexrealtimepcrkitincomparisonwiththebiofirerespiratorypanel
AT yunsunae performanceevaluationofthepowercheksarscov2influenzaabmultiplexrealtimepcrkitincomparisonwiththebiofirerespiratorypanel
AT jangjahyun performanceevaluationofthepowercheksarscov2influenzaabmultiplexrealtimepcrkitincomparisonwiththebiofirerespiratorypanel
AT huhheejae performanceevaluationofthepowercheksarscov2influenzaabmultiplexrealtimepcrkitincomparisonwiththebiofirerespiratorypanel
AT kimjongwon performanceevaluationofthepowercheksarscov2influenzaabmultiplexrealtimepcrkitincomparisonwiththebiofirerespiratorypanel
AT leenamyong performanceevaluationofthepowercheksarscov2influenzaabmultiplexrealtimepcrkitincomparisonwiththebiofirerespiratorypanel